Descripción del proyecto
Los embriones sintéticos ayudan a estudiar el desarrollo embrionario
El período de desarrollo embrionario es fundamental para la supervivencia y la aptitud de cualquier organismo. Sin embargo, el estudio de la embriogénesis humana se ha visto obstaculizado por la disponibilidad limitada de embriones humanos y hay muchos aspectos que siguen sin estar claros. El equipo del proyecto BLASTOID, financiado con fondos europeos, tiene por objeto desarrollar embriones sintéticos a partir de células madre humanas que se ensamblen en blastocistos en fase de preimplantación. Junto con los organoides uterinos, estos blastoides ayudarán a los investigadores a estudiar el proceso de embriogénesis e implantación. Dado que estas células madre pueden modificarse genéticamente, constituyen una valiosa herramienta «in vitro» para estudiar fármacos que mejoren la implantación.
Objetivo
The first weeks of human embryonic development are crucial. Early abnormalities or insults result not only in infertility, but also contribute to long-term impairment of human health (e.g. cardiovascular disease and diabetes). Managing the onset of pregnancy therefore offers a huge opportunity to improve public health through effective family planning and disease prevention.
To better manage pregnancy, biomedical research would require large numbers of human embryos for use in genetic and drug screening. Unfortunately, however, the scarcity of human embryos makes this impossible. Recently, hope for an alternative approach has come from work in my lab showing that mouse stem cells self-organize into structures closely resembling pre-implantation embryos (a.k.a. blastocysts), that we termed blastoids. Because stem cells can be largely expanded and genetically-modified, these synthetic embryos provide a powerful, scalable alternative that is amenable to drug and genetic screens, thus opening numerous possibilities for therapeutic breakthroughs.
Here, I propose the development of human blastoids and uterine organoids to model embryogenesis and uterine implantation in vitro. This platform will be used to identify potential targets for the therapeutic modulation of the molecular pathways that control (1) early embryogenesis and (2) interactions between the embryo and uterus, and will pave the way to (3) establishing a drug discovery pipeline for the management of implantation.
This project will generate key insights into druggable molecules controlling early human embryogenesis, facilitating identification of therapeutic targets to improve in vitro fertilization (IVF) procedures and contraception and, ultimately, to prevent several chronic diseases.
Ámbito científico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesdevelopmental biology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineobstetrics
- medical and health sciencesclinical medicineembryology
Programa(s)
Régimen de financiación
ERC-COG - Consolidator GrantInstitución de acogida
1030 Wien
Austria